30 results about "Cytology sample" patented technology

Conjugate compositions are disclosed that include a specific-binding moiety covalently coupled to a nanoparticle through a heterobifunctional polyalkyleneglycol linker. In one embodiment, a conjugates is provided that includes a specific-binding moiety and a fluorescent nanoparticle coupled by a heterobifunctional PEG linker. Fluorescent conjugates according to the disclosure can provide exceptionally intense and stable signals for immunohistochemical and in situ hybridization assays on tissue sections and cytology samples, and enable multiplexing of such assays.

Antibody / signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.

The present invention involves methods, systems, and devices for analyzing a biological material, such as a cellular or other specimen. The method includes placing the specimen on a substrate having different capture regions, such as contiguous layers, wherein the different capture regions of the substrate contain different identification molecules, and transferring components of the specimen through the capture regions under conditions that allow the components to interact with different identification molecules in the different regions of the substrate. The components of the specimen can be transferred through the different layers (or other regions) of the substrate by capillary action of a solution moving through the cellular specimen or by electrophoresis. The transfer of components of the specimen through the substrate may occur while maintaining a geometric correspondence to the specimen, such as the cytoarchitecture of a cellular specimen, for example by moving the components through parallel layers having positions that correspond to positions within the specimen. When the cellular architecture of the specimen is maintained, a correlation between the different identification molecules and the components of the cellular specimens may be made. The analysis can occur with one or more different discrete (for example cellular) specimens on a surface of the substrate. Examples of cellular specimens include, but are not limited to tissue sections, particularly tumor tissue sections. The cellular specimen can also include cultured cells or a cytology sample. Cytostat tissue sections cut slightly thicker than usual, that is about 25 to about 50 μm, improves the ability to detect molecules of moderate and low level abundance.

Antibody / signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention relates to methods of categorizing a cervical tissue or cytology sample by performing an in situ hybridization assay using an antisense E6 or E7 probe on a cervical tissue sample, wherein the antisense E6 or E7 probe can simultaneously detect HPV DNA and HPV RNA; detecting the presence of HPV nucleic acid; and categorizing the cervical tissue sample based on HPV nucleic acid expression.

A cytological cell sample collection, storage, and transport device is disclosed. The device comprises a sheath, a collection assembly, a base, and a containment vial. The collection assembly is slidably coupled to the base to expose a swab head comprising the collection assembly. The containment vial is configured to enclose the sheath and collection assembly within the internal volume defined by the containment vial and the base.

The present invention relates to the analysis of specimens. Specifically, the invention relates to methods and apparatus for reviewing specimen slides, including apparatus for holding the slides. The invention also relates to an automatic focusing method for an imaging system and methods for accommodating vibration in the imaging system. In particular, the methods and apparatus may be applied to the automated analysis of cytological specimen slides.

Methods for quantifying an HPV protein expression in a clinical sample are disclosed. The quantifying methods include the process for obtaining the clinical sample. Such a clinical sample is consisted of a population of cells that are susceptible to infection by an HPV. The quantifying methods also include the process for depositing the clinical sample into a container. The clinical sample is contacted with the first antibody that specifically binds to an HPV protein which is expressed by an HPV-infected cell under a condition that promotes specific binding of the first antibody to the HPV protein expressed by the population of cells. The methods further include the process for quantifying the specific binding of the first antibody and thereby quantifying the HPV protein expression in the clinical sample. The assay provides an objective test to identify patients with high-grade precursor from cytology samples before biopsy.

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The present invention relates to the analysis of cytological material. Specifically, the invention relates to stains and methods of producing the stains, methods of staining cells for cytological or histological analysis to contrast the nuclear portion of the cell from the cytoplasmic portion, and systems and methods for illuminating a cytological sample. The analysis can be automated or manual.

A treatment device (1) for treating histological or cytological samples has a plurality of containers (6) for different treatment agents and a detection apparatus (2) for detecting a code which unequivocally identifies a type of a treatment agent or a type of a group of treatment agents from a package or replacement container of a treatment agent or group of treatment agents. The device furthermore has an evaluation apparatus (18) that, based on a detected code, ascertains which of the containers is or are to be replenished or replaced, and an indicating apparatus (4) which communicates to a user the ascertained container (6) or containers (6) that is or are to be replenished or replaced. The indicating apparatus may include a display (5) presenting a schematic image of the plurality of containers (6) with image(s) of each ascertained container being marked, and / or a light source (15) that illuminates each ascertained container.

The present invention is related to a system or kit for preparing a cytological sample for examination, which comprises a fixative for fixing cells comprised in said sample, a cell surface modifier for modification of the surface of cells comprised in said sample, a first sample support meanshaving at least two sides, and a second sample support means having at least two sides, wherein on at least one side of at least one of the support means a cytoplasmic stain or a nuclear stain is deposited (Fig. 1).

Disclosed is a method for detecting cells having at least one anomaly in a cytological sample on the basis of at least one first digitised digitised-electron-microscopy image of the sample.

An efficient manual method for preparing a cytology sample for staining. According to the method, a biological sample is provided, wherein the biological sample is a liquid-based cytology sample. A slide is placed in a holder adapted for receiving the slide. The slide is pre-coated with a composition that will cause cells to adhere to the slide. A settling chamber is placed over said slide and thesettling chamber is locked onto the holder. The settling chamber has openings in both proximate and distal ends. The opening in the distal end of the settling chamber is positioned over the slide such that the slide is interposed between the holder and the settling chamber and the slide is in fluid communication with the settling chamber. A density reagent is then dispensed into the settling chamber. The liquid-based cytology sample is then dispensed into the settling chamber over the reagent. The assembly formed by the holder, slide and settling chamber (and its liquid contents) is placed ina centrifuge. The assembly is centrifuged for less than 5 minutes at a rotation force of less than 500g. The density reagent and the liquid thereover are decanted from the settling chamber. The settling chamber is removed from over the slide. The slide is removed from the holder for staining.